CDKI-73 Inhibitor

Name: CDKI-73 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754692
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754692

CDKI-73 is a potent CDK9 inhibitor (Ki: 4nM). It shows selective toxicity to CLL cells (LD50: 80nM) versus normal B cell and normal CD34+ cell (LD50>20uM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

CDKI-73, Inhibitor

Full Product Name

CDKI-73

Product Gene Name

CDKI-73, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

394.45

Solubility

DMSO: 52mg/mL (131.83mM)
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C15H15FN6O2S2

SMILES

CNC1=NC(C)=C(C2=C(F)C=NC(NC3=CC(S(=O)(N)=O)=CC=C3)=N2)S1

CAS Number

1421693-22-2

Target & IC50

CDK2: ic50 3.27nM
CDK9: ic50 5.78nM
CDK1: ic50 8.17nM
CDK4: ic50 8.18nM
CDK6: ic50 37.68nM
CDK7: ic50 134.26nM

In Vitro

After a single intravenous bolus dose at 2mg/kg and an oral dose at 10mg/kg in mice, CDKI-73 exhibited a favorable pharmacokinetic profile with oral bioavailability of F = 56% [1].

Product Categories/Family for CDKI-73, inhibitor

Cell Cycle/Checkpoint; CDK

Product References and Citations for CDKI-73, inhibitor

Xie S, et al. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin. 2016 Nov;37(11):1481-1489.
Xie S, et al. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin. 2016 Nov;37(11):1481-1489.
Lam F, et al. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget. 2014 Sep 15;5(17):7691-704.
Lam F, et al. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget. 2014 Sep 15;5(17):7691-704.

Other Notes

Small volumes of CDKI-73, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for CDKI-73 purchase

MBS5754692 is an inhibitor targeting CDKI-73.